Reprint

10th Anniversary of Biomedicines—Translational Laboratory and Experimental Medicine for the Sake of Neurological Diseases and Mental Illnesses

Edited by
June 2024
422 pages
  • ISBN978-3-7258-1267-7 (Hardback)
  • ISBN978-3-7258-1268-4 (PDF)

This is a Reprint of the Special Issue 10th Anniversary of Biomedicines—Translational Laboratory and Experimental Medicine for the Sake of Neurological Diseases and Mental Illnesses that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The 10th Anniversary of Biomedicines—Translational Laboratory and Experimental Medicine for the Sake of Neurological Diseases and Mental Illnesses features a collection of 21 groundbreaking papers commemorating a decade of pioneering research into the complexities of the human mind, neurological diseases, and mental illnesses. This reprint explores the complex interactions that occur within the human brain, including neuroplasticity, cognitive responses, and the influence of aging and pathological conditions on behavior. Researchers and clinicians have dedicated themselves to bridging the gap between laboratory discoveries and clinical applications, unraveling the mysteries of brain function and mental health, and proposing novel therapeutic approaches and potential advances in the field. This articles included in this Special Issue crucially elucidate the mechanisms that underpin neurological disorders and mental illnesses by investigating neural circuits, plasticity, and brain adaptation. From studying the brain's ability to recover after a stroke to investigating the relationship between neural activity and cognitive function, this collection of papers exemplifies the unwavering dedication and innovation of biomedicine. As we commemorate a decade of groundbreaking research, these findings pave the way for future studies that aim to enhance the lives of people suffering from neurological conditions and mental health illnesses.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
gaze perception; gaze-cueing; neuroimaging; superior temporal sulcus; amygdala; neurologic patients; neurocognitive mechanisms; non-invasive brain stimulation; febrile seizure; induced pluripotent stem cells; mesial temporal lobe epilepsy; voltage gated sodium channel NaV1.1; disease model; intentional forgetting; directed forgetting; fMRI; neuroimaging; meta-analysis; Activation Likelihood Estimation (ALE); Latent Dirichlet Allocation (LDA); brainstem; cerebellum; cerebral infarction; cerebrovascular diseases; dizziness; imbalance; stroke; stroke registry; vertebrobasilar insufficiency; vertigo; dopamine (DA); norepinephrine (NE); dopamine transporter knockout (DAT-KO) rats; ADHD model; guanfacine (GF); spatial working memory; attention; brain-derived neurotrophic factor; serum; trajectory; major depression; first-episode; drug-naïve; Diagnostic and Statistical Manual of Mental Disorders Fifth Edition; Hamilton Rating Scale for Depression; paroxetine; escitalopram; duloxetine; multiple sclerosis; PPMS; SPMS; tryptophan; kynurenine; cuprizone; demyelination; remyelination; animal model; translational; neuroinflammation; inflammasomes; NLRP3; inhibitors; brain; neurodegenerative diseases; virus encephalitis; innate immunity; alcohol; brain; neurogenesis; subventricular zone; dentate gyrus; ischemia; reperfusion; rotarod test; open field test; mice; Parkinson’s disease; gut–brain axis; enteric nervous system; central nervous system; neurons; glia cells; non-motor symptoms; gastrointestinal dysfunction; microbiota; rodent models; clinical evidence; aging; platelet; mitochondria; respiratory chain complex; mitochondrial respiration; cognitive decline; neurodegenerative disease; neuroinflammation; neuroplasticity; oxidative stress; autism spectrum disorder; brain derived neurotrophic factor; biomarkers; homocysteine; interleukin-6; inflammation; kynurenine pathway; serotonin; suicidality; suicidal behavior; tryptophan; UBL3; α-synuclein; interaction; drug screen; EGFR pathway inhibitor; osimertinib; downregulate; α-synucleinopathies; melatonin; anxiety; mice; adolescents; adults; local field potentials; hippocampus; medial prefrontal cortex; sociability; aging; ketamine; NMDA; pharmacological response; locomotion; psychosis; learning; age; strain; dose effect; genetic diversity; lower back pain; mental illness; pain catastrophizing; artificial intelligence (AI); motor disability; pain perception; affective components; central nervous system; emotions; peripheral nervous system; sensation; amyotrophic lateral sclerosis; neuropathology; death; axon outgrowth; electrical activity; dental pulp stem cell; conditioned medium; neurotrophic factors; motoneuron; cell therapy; stroke; gut; dysbiosis; nutrition; inflammation; microbiota; mortality; therapeutics; blood; brain; neurodegeneration; osteopenia; osteoporosis; sarcopenia; spinal cord injury; ischemic stroke; virtual reality; electroencephalography; neural plasticity; cognitive rehabilitation; brain injury; outcome measures; clinical trial; neurological disorders; brainstem; cerebellum; cognition; diaschisis; executive function; functional NIRS; near-infrared spectroscopy; SPECT; supplementary motor area; thalamus; n/a